Benefit of a wearable cardioverter defibrillator for detection and therapy of arrhythmias in patients with myocarditis
Abstract Aims Myocarditis may lead to malignant arrhythmias and sudden cardiac death. As of today, there are no reliable predictors to identify individuals at risk for these catastrophic events. The aim of this study was to evaluate if a wearable cardioverter defibrillator (WCD) may detect and treat...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-08-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.13353 |
| _version_ | 1819155519051399168 |
|---|---|
| author | Verena Tscholl Dennis Wielander Felicitas Kelch Andrea Stroux Philipp Attanasio Carsten Tschöpe Ulf Landmesser Mattias Roser Martin Huemer Bettina Heidecker Patrick Nagel |
| author_facet | Verena Tscholl Dennis Wielander Felicitas Kelch Andrea Stroux Philipp Attanasio Carsten Tschöpe Ulf Landmesser Mattias Roser Martin Huemer Bettina Heidecker Patrick Nagel |
| author_sort | Verena Tscholl |
| collection | DOAJ |
| description | Abstract Aims Myocarditis may lead to malignant arrhythmias and sudden cardiac death. As of today, there are no reliable predictors to identify individuals at risk for these catastrophic events. The aim of this study was to evaluate if a wearable cardioverter defibrillator (WCD) may detect and treat such arrhythmias adequately in the peracute setting of myocarditis. Methods and results In this observational, retrospective, single centre study, we reviewed patients presenting to the Charité Hospital from 2009 to 2017, who were provided with a WCD for the diagnosis of myocarditis with reduced ejection fraction (<50%) and/or arrhythmias. Amongst 259 patients receiving a WCD, 59 patients (23%) were diagnosed with myocarditis by histology. The mean age was 46 ± 14 years, and 11 patients were women (19%). The mean WCD wearing time was 86 ± 63 days, and the mean daily use was 20 ± 5 h. During that time, two patients (3%) had episodes of sustained ventricular tachycardia (VT; four total) corresponding to a rate of 28 sustained VT episodes per 100 patient‐years. Consequently, one of these patients underwent rhythm stabilization through intravenous amiodarone, while the other patient received an implantable cardioverter defibrillator. Two patients (3.4%) were found to have non‐sustained VT. Conclusions Using a WCD after acute myocarditis led to the detection of sustained VT in 2/59 patients (3%). While a WCD may prevent sudden cardiac death after myocarditis, our data suggest that WCD may have impact on clinical management through monitoring and arrhythmia detection. |
| first_indexed | 2024-12-22T15:38:16Z |
| format | Article |
| id | doaj.art-f12ed52b1bae4a8fb0bd7bdbaa9ee124 |
| institution | Directory Open Access Journal |
| issn | 2055-5822 |
| language | English |
| last_indexed | 2024-12-22T15:38:16Z |
| publishDate | 2021-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj.art-f12ed52b1bae4a8fb0bd7bdbaa9ee1242022-12-21T18:21:12ZengWileyESC Heart Failure2055-58222021-08-01842428243710.1002/ehf2.13353Benefit of a wearable cardioverter defibrillator for detection and therapy of arrhythmias in patients with myocarditisVerena Tscholl0Dennis Wielander1Felicitas Kelch2Andrea Stroux3Philipp Attanasio4Carsten Tschöpe5Ulf Landmesser6Mattias Roser7Martin Huemer8Bettina Heidecker9Patrick Nagel10Department of Cardiology Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin Hindenburgdamm 30 12203 Berlin GermanyDepartment of Cardiology Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin Hindenburgdamm 30 12203 Berlin GermanyDepartment of Cardiology Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin Hindenburgdamm 30 12203 Berlin GermanyInstitute for Biometry and Clinical Epidemiology and Berlin Institute of Health (BIH) Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin Berlin GermanyDepartment of Cardiology Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin Hindenburgdamm 30 12203 Berlin GermanyBerlin Institute of Health at Charite (BIH)‐ Universitätsmedizin Berlin BIH Center for Regenerative Therapies (BCRT), Charité ‐ University Medicine Berlin, Campus Virchow Clinic Augustenburgerplatz 1 13353 Berlin GermanyDepartment of Cardiology Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin Hindenburgdamm 30 12203 Berlin GermanyDepartment of Cardiology Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin Hindenburgdamm 30 12203 Berlin GermanyDepartment of Cardiology Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin Hindenburgdamm 30 12203 Berlin GermanyDepartment of Cardiology Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin Hindenburgdamm 30 12203 Berlin GermanyDepartment of Cardiology Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin Hindenburgdamm 30 12203 Berlin GermanyAbstract Aims Myocarditis may lead to malignant arrhythmias and sudden cardiac death. As of today, there are no reliable predictors to identify individuals at risk for these catastrophic events. The aim of this study was to evaluate if a wearable cardioverter defibrillator (WCD) may detect and treat such arrhythmias adequately in the peracute setting of myocarditis. Methods and results In this observational, retrospective, single centre study, we reviewed patients presenting to the Charité Hospital from 2009 to 2017, who were provided with a WCD for the diagnosis of myocarditis with reduced ejection fraction (<50%) and/or arrhythmias. Amongst 259 patients receiving a WCD, 59 patients (23%) were diagnosed with myocarditis by histology. The mean age was 46 ± 14 years, and 11 patients were women (19%). The mean WCD wearing time was 86 ± 63 days, and the mean daily use was 20 ± 5 h. During that time, two patients (3%) had episodes of sustained ventricular tachycardia (VT; four total) corresponding to a rate of 28 sustained VT episodes per 100 patient‐years. Consequently, one of these patients underwent rhythm stabilization through intravenous amiodarone, while the other patient received an implantable cardioverter defibrillator. Two patients (3.4%) were found to have non‐sustained VT. Conclusions Using a WCD after acute myocarditis led to the detection of sustained VT in 2/59 patients (3%). While a WCD may prevent sudden cardiac death after myocarditis, our data suggest that WCD may have impact on clinical management through monitoring and arrhythmia detection.https://doi.org/10.1002/ehf2.13353Wearable cardioverter defibrillatorMyocarditisHFrEFHFmrEF |
| spellingShingle | Verena Tscholl Dennis Wielander Felicitas Kelch Andrea Stroux Philipp Attanasio Carsten Tschöpe Ulf Landmesser Mattias Roser Martin Huemer Bettina Heidecker Patrick Nagel Benefit of a wearable cardioverter defibrillator for detection and therapy of arrhythmias in patients with myocarditis ESC Heart Failure Wearable cardioverter defibrillator Myocarditis HFrEF HFmrEF |
| title | Benefit of a wearable cardioverter defibrillator for detection and therapy of arrhythmias in patients with myocarditis |
| title_full | Benefit of a wearable cardioverter defibrillator for detection and therapy of arrhythmias in patients with myocarditis |
| title_fullStr | Benefit of a wearable cardioverter defibrillator for detection and therapy of arrhythmias in patients with myocarditis |
| title_full_unstemmed | Benefit of a wearable cardioverter defibrillator for detection and therapy of arrhythmias in patients with myocarditis |
| title_short | Benefit of a wearable cardioverter defibrillator for detection and therapy of arrhythmias in patients with myocarditis |
| title_sort | benefit of a wearable cardioverter defibrillator for detection and therapy of arrhythmias in patients with myocarditis |
| topic | Wearable cardioverter defibrillator Myocarditis HFrEF HFmrEF |
| url | https://doi.org/10.1002/ehf2.13353 |
| work_keys_str_mv | AT verenatscholl benefitofawearablecardioverterdefibrillatorfordetectionandtherapyofarrhythmiasinpatientswithmyocarditis AT denniswielander benefitofawearablecardioverterdefibrillatorfordetectionandtherapyofarrhythmiasinpatientswithmyocarditis AT felicitaskelch benefitofawearablecardioverterdefibrillatorfordetectionandtherapyofarrhythmiasinpatientswithmyocarditis AT andreastroux benefitofawearablecardioverterdefibrillatorfordetectionandtherapyofarrhythmiasinpatientswithmyocarditis AT philippattanasio benefitofawearablecardioverterdefibrillatorfordetectionandtherapyofarrhythmiasinpatientswithmyocarditis AT carstentschope benefitofawearablecardioverterdefibrillatorfordetectionandtherapyofarrhythmiasinpatientswithmyocarditis AT ulflandmesser benefitofawearablecardioverterdefibrillatorfordetectionandtherapyofarrhythmiasinpatientswithmyocarditis AT mattiasroser benefitofawearablecardioverterdefibrillatorfordetectionandtherapyofarrhythmiasinpatientswithmyocarditis AT martinhuemer benefitofawearablecardioverterdefibrillatorfordetectionandtherapyofarrhythmiasinpatientswithmyocarditis AT bettinaheidecker benefitofawearablecardioverterdefibrillatorfordetectionandtherapyofarrhythmiasinpatientswithmyocarditis AT patricknagel benefitofawearablecardioverterdefibrillatorfordetectionandtherapyofarrhythmiasinpatientswithmyocarditis |